New Treatment for Irritable Bowel Syndrome (IBS)

 

Welcome to Weekly Health Update


“A critical weekly review of important new research findings for health-conscious readers”


NEW TREATMENT FOR IRRITABLE BOWEL SYNDROME (IBS)

An estimated 10 to 20 percent of the population suffers from a complex of gastrointestinal symptoms that are collectively referred to as Irritable Bowel Syndrome (IBS).  Irritable Bowel Syndrome affects women three times more commonly than men, and has historically been considered a “wastebasket” diagnosis for patients with functional gastrointestinal (GI) complaints when no other specific diagnosis can be found. 

While the precise causes of IBS are not well understood at this time, various theories have been proposed.  These include abnormal responses to infections of the GI tract, abnormal hormonal and neurological function of the GI tract, hypersensitivity to certain types of foods, abnormal motility of the colon, a “hyper-awareness” of bodily functions, and certain psychiatric conditions, in addition to other hypotheses.  (It is almost certain, however, that there is more than one cause for IBS.)

There are a variety of symptoms that have been associated with IBS, and the incidence, severity and frequency of each of these symptoms varies considerably from one IBS patient to another.  Typically, however, IBS-associated symptoms include bloating, crampy abdominal pain, diarrhea alternating with periods of constipation, and the passage of clear or white mucus from the rectum.  In many cases, IBS symptoms are more pronounced after eating, and patients with IBS often experience a powerful urge to move their bowels after meals.  IBS symptoms are also more frequent and more severe during times of stress.  In women with IBS, these distressing GI symptoms may become more intense around the time of their menstrual periods.  Other symptoms that have been commonly observed in patients with IBS include heartburn, nausea, and vomiting.

Because the precise causes of IBS are poorly understood, there have been a wide range of treatments recommended for this syndrome.  For example, exercise and other stress-reducing activities may be helpful for some IBS sufferers.  Giving up tobacco, and reducing or eliminating alcohol consumption may also help to reduce IBS symptoms, while promoting improved overall health at the same time.  Keeping a food diary can also help to identify foods that tend to provoke or worsen IBS symptoms in many patients.  Finally, dietary fiber supplementation has been almost universally advocated by most IBS experts.  Unfortunately, for many IBS sufferers, these and other recommended treatments for IBS are often ineffective. 

A new prospective, randomized, placebo-controlled clinical research study, just published in the journal Gut, has evaluated a new medical treatment for IBS that may hold promise for some of the millions of people who suffer from the unpleasant symptoms of this condition.  This small clinical research study included 60 patients with IBS.  Half of these IBS patients were randomized to receive an antihistamine medication (ketotifen) that prevents inflammatory “mast cells” from releasing inflammatory substances.  (Mast cells are present throughout the body, including the respiratory tract and the GI tract; and when stimulated, they release histamine and other substances that cause swelling and inflammation of adjacent tissues.)  The remaining half of this group of study volunteers was secretly randomized to receive an identical placebo (sugar) pill.  This study lasted for 8 weeks, altogether. 

At the start of this prospective clinical study, the 60 patient volunteers with IBS underwent an initial “barostat” study of the rectum.  This test involves the insertion of a balloon-like device into the rectum.  The balloon is then slowly inflated, which distends the rectal wall.  Prior studies have shown that many IBS patients perceive rectal discomfort with significantly less rectal distension than patients without IBS, a response that has been termed “visceral hypersensitivity.”  One theory as to why IBS patients experience visceral hypersensitivity relates to the abnormal activation of mast cells in the GI tract which, in turn, release multiple substances, including histamine, that generate an inflammatory response.

The 60 IBS patient volunteers also underwent biopsies of the rectum, and the results of these biopsies were compared with rectal biopsies taken from 22 age- and gender-matched “control” patients without IBS.  These biopsy specimens were then assessed for the number of inflammatory mast cells present, as well as the extent to which these mast cells spontaneously released inflammatory substances such as histamine and tryptase.

At the end of the 8-week study, the 60 IBS patient volunteers underwent a repeat barostat study of the rectum.  Among the IBS patient volunteers who experienced visceral hypersensitivity at the time of their initial barostat study, ketotifen significantly reduced the severity of visceral hypersensitivity when compared to similar patients who had been secretly randomized to receive placebo pills.  (There was no apparent change in visceral sensitivity associated with ketotifen among the IBS patients who had a normal response to initial barostat testing, however.)  More importantly, the IBS patients who had secretly been randomized to receive ketotifen reported significant improvement in abdominal pain and the other classic symptoms of IBS, when compared to the patient who had been randomized to receive placebo pills.  At the same time, the results of the rectal biopsies actually revealed fewer mast cells in the rectal biopsy specimens of IBS patients when compared to the control patients.  Moreover, there was only a very slight increase in histamine release by these rectal mast cells observed in IBS patients, when compared to the control patients.  (These latter two observations call into question the theory that increased numbers of mast cells, or/and an increased release of inflammatory substances from these mast cells, are responsible for visceral hypersensitivity in IBS patients, or for other symptoms commonly associate with IBS.  They also suggest that the favorable effects of ketotifen on the symptoms of IBS among these patient volunteers are likely occurring by a mechanism other than inhibition of mast cells within the GI tract.)

As I have noted in previous columns on this topic, there are likely multiple causes of IBS, and, therefore, individual treatments for this condition are not likely be equally effective in every patient with IBS.  However, the results of this small, early-phase study offer the hope that ketotifen (and, perhaps, other so-called “H1 antihistamines”), may be able to relieve the distressing symptoms of IBS in at in least some patients with this chronic GI syndrome.

 

To review previous columns on IBS, please select the following links:

Irritable Bowel Syndrome (IBS), Diet & Fiber

Irritable Bowel Syndrome: Cause Discovered?

 

Watch for the publication of my new landmark evidence-based book, “A Cancer Prevention Guide for the Human Race,” in September of this year.



 

Disclaimer: As always, my advice to readers is to seek the advice of your physician before making any significant changes in medications, diet, or level of physical activity


Dr. Wascher is an oncologic surgeon, a professor of surgery, a cancer researcher, an oncology consultant, and a widely published author



For a different perspective on Dr. Wascher, please click on the following YouTube link: 

Texas Blues Jam



I and the staff of Weekly Health Update would again like to take this opportunity to thank the more than 100,000 health-conscious people, from around the world, who visit our premier global health information website every month.  As always, we enjoy receiving your stimulating feedback and questions, and I will continue to try and personally answer as many of your inquiries as I possibly can.



 

Bookmark and Share



 

Post to Twitter

Enter Google AdSense Code Here

Comments

29 Comments on "New Treatment for Irritable Bowel Syndrome (IBS)"

  1. Doctorwascher on Mon, 6th Sep 2010 9:31 pm 

    Non-Compliance with Hormonal Therapy for Breast Cancer and Risk of Death…

    Weekly Health Update:

    Non-Compliance with Hormonal Therapy for Breast Cancer and Risk of Death

    “A critical weekly review of important new research findings for health-conscious readers…”

    By, Robert A. Wascher, MD, FACS…

  2. weight loss calculator on Tue, 14th Sep 2010 12:12 pm 

    trying to follow you on twitter but cant find your name

  3. admin on Tue, 14th Sep 2010 1:16 pm 

    doctorwascher

  4. Doctorwascher on Mon, 11th Oct 2010 3:22 pm 

    Mammograms Between 40 and 49 Years of Age…

    Weekly Health Update:

    Mammograms Between 40 and 49 Years of Age

    “A critical weekly review of important new research findings for health-conscious readers…”

    By, Robert A. Wascher, MD, FACS

    Updated: 10/3/2010

  5. www.doctorwascher.com on Tue, 19th Oct 2010 4:01 pm 

    Thank you.

  6. Anonymous on Thu, 3rd Feb 2011 12:21 pm 

    New treatment for irritable bowel syndrome ibs.. Amazing 🙂

  7. sarah on Thu, 7th Apr 2011 8:25 pm 

    Another great post, congratulations!

  8. Leslie on Sat, 30th Apr 2011 4:51 am 

    Great and really helpful post, honest!

  9. Muthukumar on Wed, 4th May 2011 8:05 am 

    Amazing post, honest!

  10. Shirley on Wed, 11th May 2011 2:40 pm 

    This is your best writing yet!

  11. Shirley on Mon, 16th May 2011 7:57 pm 

    Amazing post, truly!

  12. Samantha on Tue, 17th May 2011 5:46 am 

    This post is very usefull thx!

  13. Adam on Sat, 28th May 2011 3:45 am 

    Thank you sir this is a very useful post for us. keep posting.

  14. Explorer on Wed, 1st Jun 2011 8:50 am 

    Sweet blog! I found it while surfing around on Yahoo News.

  15. Brooke on Sun, 12th Jun 2011 1:47 pm 

    Howdy blogger, thank you for providing this article.. I found it first-class.

  16. Sam on Sun, 19th Jun 2011 8:41 pm 

    ome genuinely nice stuff on this website , I enjoy it.

  17. Ireir on Fri, 24th Jun 2011 1:23 am 

    http://www.doctorwascher.com is awesome !!

  18. Pennie Mcneeley on Fri, 8th Jul 2011 3:38 am 

    Excellent report and easy to fully understand explanation. How do I go about getting permission to post component of the page in my upcoming newsletter? Giving proper credit to you the article author and hyperlink to the site would not be a problem.

  19. admin on Fri, 8th Jul 2011 9:13 pm 

    As long as you reproduce the content from my website without alteration, and include attribution and copyright statements for me as the sole author, you may use my content.

    Robert A. Wascher, MD, FACS

  20. Anonymous on Tue, 26th Jul 2011 6:07 pm 

    Great info on this post. Bookmarked it! Will come back again.

  21. Marlene on Mon, 22nd Aug 2011 2:25 pm 

    You have a great weblog; greatly enjoying the articles but also believe the structure of your site is exceedingly good! Look forward to your next article! Cheers, Marlene Terando from Port-Au-Prince

  22. aldec alint on Sat, 27th Aug 2011 9:18 am 

    Hello there, You have done an incredible job. I will certainly digg it and personally suggest to my friends.

  23. Rodger on Tue, 20th Sep 2011 12:58 am 

    A lot of thanks for all of the effort on this web page.

  24. Mitchell Karamchandani on Tue, 20th Dec 2011 4:48 am 

    I have recently started a site, the info you provide on this site has helped me tremendously. Thank you for all of your time and work.

  25. Anonymous on Mon, 30th Jan 2012 3:27 am 

    I think this web site has got some very good info for everyone!

  26. Anonymous on Thu, 9th Feb 2012 9:22 am 

    very interesting topic , great post.

  27. Flo on Sat, 17th Mar 2012 8:07 pm 

    Oh my, good work on this info. I’m really impressed.

  28. Travis on Mon, 19th Mar 2012 4:21 pm 

    I have to say that for the past couple of hours i have been hooked by the impressive articles on this blog. Keep up the wonderful work.

  29. Anonymous on Sun, 25th Mar 2012 7:31 am 

    Awesome article. I will add you to my bookmarks.

Better Tag Cloud